
Nicolle J M Besselink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6683668/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide analysis of somatic noncoding mutation patterns in cancer. Science, 2022, 376, eabg5601.	12.6	33
2	GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing. Genome Biology, 2021, 22, 202.	8.8	73
3	Reconstructing single-cell karyotype alterations in colorectal cancer identifies punctuated and gradual diversification patterns. Nature Genetics, 2021, 53, 1187-1195.	21.4	37
4	Precancerous liver diseases do not cause increased mutagenesis in liver stem cells. Communications Biology, 2021, 4, 1301.	4.4	9
5	The mutational impact of culturing human pluripotent and adult stem cells. Nature Communications, 2020, 11, 2493.	12.8	61
6	5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. Nature Communications, 2019, 10, 4571.	12.8	143
7	Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer. Genome Research, 2019, 29, 1067-1077.	5.5	66
8	Early divergence of mutational processes in human fetal tissues. Science Advances, 2019, 5, eaaw1271.	10.3	24
9	Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia. Scientific Reports, 2019, 9, 1875.	3.3	7
10	Prioritization of genes driving congenital phenotypes of patients with de novo genomic structural variants. Genome Medicine, 2019, 11, 79.	8.2	19
11	The molecular genetic make-up of male breast cancer. Endocrine-Related Cancer, 2019, 26, 779-794.	3.1	27
12	Measuring mutation accumulation in single human adult stem cells by whole-genome sequencing of organoid cultures. Nature Protocols, 2018, 13, 59-78.	12.0	52
13	<i>TP53</i> mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in <i>TP53</i> wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. Oncotarget, 2016, 7, 58435-58444.	1.8	8
14	Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice. American Journal of Clinical Pathology, 2015, 143, 573-578.	0.7	41
15	Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology. Journal of Molecular Diagnostics, 2015, 17, 10-18.	2.8	35
16	Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report. Anticancer Research, 2015, 35, 3399-403.	1.1	2
17	Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes. PLoS ONE, 2014, 9, e103988.	2.5	319